Tezacaftor, Ivacaftor Combination Generally Safe, Well Tolerated in Children With CF Under Age 12
Data from a phase 3 trial are supporting the use of tezacaftor in combination with ivacaftor for the treatment of cystic fibrosis (CF) in...
Different CFTR Potentiators Bind to Same Flexible Spot on Protein, Study Finds
Approved and investigative cystic fibrosis (CF) treatments known as CFTR potentiators work by binding to the same flexible protein spot —...
Kalydeco’s Safety and Benefits Studied in CF Patients with Severe Lung Disease
Treatment with Kalydeco (ivacaftor) improved lung function, exercise capacity, and sweat chloride concentration in cystic fibrosis (CF)...
FDA Approves Symdeko for Treatment of CF Children, Ages 6 to 11, with Certain CFTR Mutations
The U.S. Food and Drug Administration (FDA) has approved Symdeko (tezacaftor/ivacaftor and ivacaftor) tablets for the treatment of...
FDA Approves Kalydeco for Treatment of 6- to 12-month-old Infants with Cystic Fibrosis
The U.S. Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) for the treatment of infants from six to 12 months old, who...
Cystic fibrosis drug combo found safe and effective for 2–5 year olds
An open label phase 3 study conducted at Ann & Robert H. Lurie Children’s Hospital of Chicago and other centers established that a...